Jan 14, 2020 / 05:00PM GMT
James Daniel Gordon - JP Morgan Chase & Co, Research Division - Senior Analyst
Good morning. I'm James Gordon, JPMorgan European Healthcare Analyst. And today, I've got the pleasure of introducing the Alcon presentation. So you're going to hear from Alcon's CEO, David Endicott. And we're going to have a breakout after this in the Olympic room. So I hope you can join us for that. And with that said, thanks very much for joining us. I look forward to the presentation.
David J. Endicott - Alcon, Inc. - CEO & Director
Thank you very much. Good morning. For 70-plus years or so, Alcon has been focused on eye care, but the last 10 months or so, we have become completely independent again. So although many of you may know us, we really are at this point in a new issue. And so what I'd like to do maybe this morning is spend a little bit of time to give you a bit of background on our market fundamentals, and then remind you of the turnaround plan we started some time ago, 2016 with the Novartis team. And then really give you a sense of what our investment thesis
Alcon AG at 38th Annual J.P Morgan Healthcare Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers